{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_codes_comments in Code Comments (approximate match)
Status:
Investigational
Source:
INN:efdoralprin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00005569: Phase 1 Interventional Completed Healthy
(2000)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:773920
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
EU-Orphan Drug:EU/3/03/138
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
Infergen
(1997)
Source URL:
First approved in 1997
Source:
Infergen
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00172809: Phase 4 Interventional Completed Chronic Hepatitis C
(2005)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
